Ether (ETH) price increased by 1.26% to $2,419 within one hour on October 20, driven mainly by $8.24 million in short position liquidations on Binance, Bybit, and OKX. This surge outpaced long liquidations, which totaled $240,000, indicating strong short squeeze pressure. Ether's market capitalization stood at approximately $293 billion, maintaining its position as the second-largest cryptocurrency by value. These movements highlight active trading dynamics and potential volatility in the ETH market.
Ether's price rose by 1.26% to $2,419 within one hour, as reported on October 20. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 21, 2026 05:11 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell today. Notable movers include COMP (Compound) with a 1-day change of +23.17% and a Pluang order activity split of 32% Sell / 68% Buy, THETA (Theta Network) down 100% Sell order activity with an 11.62% gain, and BAL (Balancer) up 11.14% with a typical hold time of 85 days.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
